SEC Form D raise Raised $34.33M in debt securities (Form D filed Dec 18, 2025); since then posted 6 roles. SEC Form D 0000905148-25-004422 (Dec 18, 2025)Evidence (1 event)
Dec 18, 2025 · SEC Form D 0000905148-25-004422 Name of Issuer: Delfi Diagnostics, Inc.; CIK: 1783735; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 34333315; Federal exemptions: 06b
Trial start Not phased (device or behavioral study): Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer source ↗
Trial start —: CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung source ↗
Trial start —: DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
